Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
Open Access
- 14 October 2025
- journal article
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (4) , 939-949
Abstract
Background: Patients with migraine aged ≥65 years old are underrepresented in clinical trials. This study compares effectiveness, excellent response, and tolerability of galcanezumab in patients ≥65 years and those younger than 65 years, specifically assessing age as a predictor of response. Methods: This real‐life, multicenter cohort study included patients with chronic or high‐frequency episodic migraine who did not respond to more than or equal to three preventive drugs, treated with galcanezumab, and followed for 12 months from 12 Spanish hospitals, between November 2019 and January 2022. Effectiveness was defined as ≥50% reduction in monthly headache days (MHD), and excellent response as ≥75% reduction at 6 months. Tolerability was based on the percentage of patients discontinuing due to adverse events. Results: We included 1055 patients (934 patients p = 0.045], but lower HIT‐6 scores [67 (IQR 63–72) vs. 69 (66–73), p < 0.001]. Effectiveness was similar across age groups at 3 (57.0% vs. 48.8%, p = 0.090), 6 (57.0% vs. 51.8%, p = 0.281), and 12 months (52.1% vs. 51.4%, p = 0.889). However, excellent response was more frequent in the ≥65 years group at 3 months (32.2% vs. 23.1%, p = 0.028) and 6 months (33.9% vs. 23.5%, p = 0.012), with a non‐significant difference at 12 months (33.1% vs. 25.4%, p = 0.071). Tolerability was comparable within age groups (5.8% discontinuation due to adverse effects in patients ≥65 years vs. 6.7% in patients p = 0.837). Age was independently associated with effectiveness (adjusted odds ratio [aOR]: 1.02; 95% confidence interval [CI]: 1.004–1.03) and excellent response (aOR: 1.02; 95% CI: 1.01–1.04). A statistically significant association was found in the logistic regression model for excellent response when age was dichotomized at 65 years, with increasing age linked to a higher likelihood of an excellent treatment response (aOR: 1.79; 95% CI: 1.13–2.82, p = 0.012). Conclusions: Galcanezumab is as effective and well‐tolerated in patients aged ≥65 years as in younger patients but older patients showed a higher rate of excellent response. Age is associated with a better response to galcanezumab. imageKeywords
This publication has 26 references indexed in Scilit:
- Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in MigraineAnnals of Neurology, 2022
- Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal studyNeurological Sciences, 2022
- Eptinezumab for migraine prevention in patients 50 years or olderActa Neurologica Scandinavica, 2022
- Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)Clinical Drug Investigation, 2022
- Diagnosis and management of migraine in ten stepsNature Reviews Neurology, 2021
- Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)Neurological Sciences, 2020
- MigraineNeurologic Clinics, 2019
- Evaluation of Galcanezumab for the Prevention of Episodic MigraineJAMA Neurology, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- A six-item short-form survey for measuring headache impact: The HIT-6™Quality of Life Research, 2003